The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 23.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
Signature Bank
SBNY · PNK · USD · Market cap $60M
FAIL · Does not pass the screenPrice as of 3 Nov 2026Daily close, not a live quote
Screened 2026-11-03 · the tape above runs as of 07:18 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price0.18 USD at the 3 Nov 2026 close
- Fair valueUnder review: its inputs are 13 days old; there is no analyst estimate to cross-check it.
- Our regime readMarkdown, as of 3 Nov 2026
- Ethical screenDoes not pass
- Last reviewed3 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-03).
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
Signature Bank holds its Markdown at $0.18. Consolidating, no directional conviction, held for 5 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 5 days |
| Price at the screen | $0.18 |
| Valuation | 0.03 trailing · 0.02 forward price to earnings |
| Values screen | FAIL |
Five Screens, Shown in Full
Does not pass. Business activity
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Financial sector: banks | Fail |
| Debt load | 0.00% | Below 33% | Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 131.67% | Below 5% | 131.7% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Signature Bank does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SBNY's ethical verdict changes
Today SBNY does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Its inputs are 13 days old; there is no analyst estimate to cross-check it. We show no fair value, margin of safety or value read built on it until the review clears.
How a fair value is estimated: discounted cash flow (DCF).
Price History & ProjectionsWhere our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 0.0xcheap for a company growing this fast |
| Trailing P/E | 0.0xvery cheap relative to earnings |
| EPS, trailing | 10.11 |
| EPS, forward | 14.65 |
| Revenue growth | +14.0%steady growth |
| Profit margin | 51.1%highly profitable on every dollar of sales |
| Return on equity | 16.9%a solid return on shareholder capital |
| Debt to equity | 0.00minimal debt: a conservative balance sheet |
| Moat | MODERATE |
| Market cap | $60M |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeSBNY trades on PNK. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 23.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 31.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 23%.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $0.65 | -23.1% | · | $769 | -23.1% |
| 2 months | $0.72 | -30.6% | · | $694 | -30.6% |
| 3 months | $0.65 | -23.1% | · | $769 | -23.1% |
| 6 months | $1.12 | -55.4% | · | $446 | -55.4% |
| 1 year | $0.85 | -41.2% | · | $588 | -41.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SBNY does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.